Literature DB >> 2572165

Improvement of diastolic function after reversal of left ventricular hypertrophy induced by long-term antihypertensive treatment with tertatolol.

B Trimarco1, N De Luca, G Rosiello, B Ricciardelli, S Betocchi, P P Filardi, M Raponi, M Condorelli.   

Abstract

In 15 previously untreated hypertensive subjects with left ventricular (LV) hypertrophy who responded favorably (supine blood pressure less than or equal to 140/90 mm Hg) to antihypertensive treatment with a nonselective beta-blocking agent, tertatolol, the effects of reversal of LV hypertrophy on systolic and diastolic function were assessed. Patients underwent echocardiographic and radionuclide studies in control conditions (phase 1), after 1 month of blood pressure normalization (phase 2), after reversal of LV hypertrophy or at least a 20% reduction of LV mass compared to basal value (phase 3) and finally, after a 1-month washout (phase 4). In phase 2, blood pressure (130 +/- 2/85 +/- 1 vs 148 +/- 4/104 +/- 1 mm Hg) and heart rate (59 +/- 1 vs 76 +/- 2 beats/min) decreased (both p less than 0.01); LV mass remained unchanged. There were improvements in peak filling rate (end-diastolic volume/s) (2.4 +/- 0.1 vs 2.0 +/- 0.1), ejection fraction (65 +/- 1 vs 61 +/- 1%) and their ratio (stroke counts/s) (3.7 +/- 0.2 vs 3.2 +/- 0.1) (all p less than 0.05). In phase 3, blood pressure and heart rate were unchanged and reversal of LV hypertrophy was accompanied by a further increase in peak filling rate (2.9 +/- 0.1), ejection fraction (69 +/- 1%) and their ratio (4.1 +/- 0.1) compared to phase 2 (all p less than 0.01). Finally, in phase 4 blood pressure and heart rate returned to the basal value, but peak filling rate (2.7 +/- 0.1) and ejection fraction (65 +/- 1%), although reduced compared to phase 3, were still higher than phase 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572165     DOI: 10.1016/0002-9149(89)90758-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Left ventricular hypertrophy: unresolved issues.

Authors:  J A Schoenberger
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  Hypertension and diastolic function.

Authors:  E Agabiti-Rosei; M L Muiesan
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Functional changes in left ventricular hypertrophy: diagnosis of impaired diastolic function in patients with hypertension.

Authors:  R Blasini; V Tiessen; A Schömig
Journal:  Clin Investig       Date:  1993

5.  Effects of bisoprolol on left ventricular hypertrophy in essential hypertension.

Authors:  E de Teresa; M González; C Camacho-Vázquez; M J Tabuenca
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

Review 6.  Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.

Authors:  Frank R Heinzel; Felix Hohendanner; Ge Jin; Simon Sedej; Frank Edelmann
Journal:  J Appl Physiol (1985)       Date:  2015-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.